The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2016
Price : $35 *
At a glance
- Drugs Telbivudine (Primary)
- Indications Chronic hepatitis; Hepatitis B; Kidney disorders; Renal impairment
- Focus Therapeutic Use
- 26 Jul 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 03 Feb 2015 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019 as reported by ClinicalTrials.gov record.
- 03 Feb 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019 as reported by ClinicalTrials.gov record.